Dr Anker Lundemose


Anker Lundemose joined Mission Therapeutics as the Chief Executive Officer in 2015.

In a biopharma career spanning over twenty-five years, Dr. Lundemose brings extensive international experience in areas of management, business development, corporate development, M&A strategy, and execution, financing as well as R&D in key therapeutic areas including oncology, neuroscience, diabetes, obesity and anti-infectives. He is a serial entrepreneur and founder of several successful biotech companies, and has a broad international pharma, biotech and investor network. He is currently Chairman of the Board at Commit Biologics, and a non-executive director on the Boards at IsomAb Ltd.

Prior to joining Mission Therapeutics, Dr. Lundemose was CEO of publicly listed Bionor Pharma, and owner and Managing Partner of BioTesch Advice & Consultancy. Previously he was co-founder and CEO of Prosidion, the UK spin-out of OSI Pharmaceuticals’ diabetes and obesity assets, which was subsequently reversed into OSI Pharmaceuticals, Inc. At OSI Pharmaceuticals, Dr. Lundemose held several senior management roles, most latterly as Executive Vice President Corporate Development & Strategy Officer, OSI, New York. Notably he was responsible for the acquisition of the DP-IV patent estate from Probiodrug generating 30 times return on investment. He was also involved in the sale of OSI Pharmaceuticals to Astellas Pharma for $4 billion.

Dr. Lundemose has been involved in a total of six biotech exits/IPOs and has held Board positions on over 12 Biotech Companies.

Dr. Lundemose is a qualified medical doctor and has a D.M.Sc and a Ph.D from the University of Aarhus, Denmark.